$DCPH опасно! Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that the Journal of Clinical Oncology has published results from its INTRIGUE Phase 3 study of QINLOCK® (ripretinib) in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib. Although QINLOCK did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, QINLOCK showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events (TEAEs) and improved tolerability.
Нравится
Не является индивидуальной инвестиционной рекомендацией
22 комментария
Ваш комментарий...
10 августа 2022 в 20:44
Бежать?
Нравится
10 августа 2022 в 20:47
@gde_ya_1807 INTRIGUE is an international, multi-center study conducted in 122 active sites across 22 countries, where 453 patients with second-line GIST were randomized to receive ripretinib (n=226) or sunitinib (n=227). Key study results include: • In patients with a KIT exon 11 primary mutation, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm (Hazard Ratio [HR] 0.88, p=0.36). In the intention-to-treat (ITT) population (n=453), ripretinib demonstrated an mPFS of 8.0 months compared to 8.3 months for the sunitinib arm (HR 1.05, nominal p value=0.72). • In patients with a KIT exon 11 primary mutation, ripretinib demonstrated an objective response rate (ORR) of 23.9% (n=39 of 163) compared to 14.6% (n=24 of 164) for sunitinib (nominal p value=0.03). In the ITT population, ripretinib demonstrated an ORR of 21.7% (n=49 of 226) compared to 17.6% (n=40 of 227) for sunitinib (nominal p value=0.27). • Ripretinib was generally well tolerated. Fewer patients in the ripretinib arm experienced Grade 3/4 treatment-emergent adverse events compared to sunitinib (41.3% vs 65.6%).
Нравится
10 августа 2022 в 20:48
Patients receiving sunitinib were three times more likely to develop Grade 3 hypertension compared to patients receiving ripretinib (26.7% vs. 8.5%) and patients receiving sunitinib were seven times more likely to develop Grade 3 palmar-plantar erythrodysesthesia compared to patients receiving ripretinib (10.0% vs. 1.3%). • Patient reported outcome measures also showed a more favorable tolerability profile for patients receiving ripretinib compared to patients receiving sunitinib. Patients receiving ripretinib experienced less deterioration in their ability to engage in either work or leisure activities during treatment, and fewer patients receiving ripretinib experienced moderate to extremely large impact on their lives due to skin toxicity across treatment cycles compared to patients receiving sunitinib.
Нравится
10 августа 2022 в 20:49
@gde_ya_1807 дадут ниже зайти, вернусь. Пока посижу посмотрю, двояко.
Нравится
10 августа 2022 в 20:51
Не нравится фраза: did not offer a statistically significant improvement in progression-free survival compared to sunitinib.
Нравится
DoDeEv
17 подписчиков20 подписок
Портфель
до 100 000 
Доходность
63,93%
Еще статьи от автора
21 сентября 2022
SNGSP люблю покупать на паникерах
11 сентября 2022
DCPH Updated Results for Vimseltinib Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients – – Preliminary Patient-Reported Outcome Data in Phase 2 Demonstrate Clinically Meaningful Improvements in Pain and Stiffness – – Updated Safety and Efficacy Data Support Ongoing Phase 3 MOTION Study – 09.11.2022 Новость 👏
29 августа 2022
#Пульсу_3_года За время использования этого сервиса, научился мониторингу FDA, изучению Pipeline различных компаний и игре на pre-FDA run, оценке рынка сбыта лекарств, ведь мой портфель на 50% - фармацевтика. Дело благое, все болеем. Да, в пульсе не без цыган, типа резана, которые загоняют всех и вся в непонятные вещи, так вот именно благодаря их существованию появилось трезвое понимание, что мыслить нужно исключительно своей головой, не слушая всех и вся, ожидая РАКЕТ и в КОСМОС. В целом, пульс - интересная задумка, если будет более моделируемой и контролируемой, станет много лучше.